Pathway-specific tumor suppression:: Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice

被引:72
作者
Philipp-Staheli, J
Kim, KH
Payne, SR
Gurley, KE
Liggitt, D
Longton, G
Kemp, CJ [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA
[2] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[3] Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S1535-6108(02)00054-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Expression of the cyclin-dependent kinase inhibitor p27(Kip1) (p27) is frequently reduced in human colorectal cancer, and this correlates with poor patient prognosis. To clarify the role of p27 in gastrointestinal (GI) cancer, we measured p27 expression, as well as the effect of germline deletion of p27, in 3 different mouse models of GI neoplasia. p27 expression was frequently reduced in GI tumors arising in 1,2-dimethylhydrazine (DMH) treated mice, and in Apc mutant Min/+ mice, but not in GI tumors arising in Smad3 mutant mice. Germline deletion of p27 resulted in accelerated tumor development and increased tumor cell proliferation in both DMH treated and Min/+ mice, but not in Smad3 mutant mice. p27 deficiency also led to increased adenoma to adenocarcinoma progression. These results indicate that reduction of p27 cooperates with mutations in Apc but not in Smad3 during GI tumorigenesis. Thus, tumor suppression by p27 is contingent on the specific oncogenic pathway that drives tumor development.
引用
收藏
页码:355 / 368
页数:14
相关论文
共 77 条
[1]   ARE ANIMAL-MODELS OF COLON CANCER RELEVANT TO HUMAN-DISEASE [J].
AHNEN, DJ .
DIGESTIVE DISEASES AND SCIENCES, 1985, 30 (12) :S103-S106
[2]   TGF-β signaling in cancer -: a double-edged sword [J].
Akhurst, RJ ;
Derynck, R .
TRENDS IN CELL BIOLOGY, 2001, 11 (11) :S44-S51
[3]   Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response [J].
Ashcroft, GS ;
Yang, X ;
Glick, AB ;
Weinstein, M ;
Letterio, JJ ;
Mizel, DE ;
Anzano, M ;
Greenwell-Wild, T ;
Wahl, SM ;
Deng, CX ;
Roberts, AB .
NATURE CELL BIOLOGY, 1999, 1 (05) :260-266
[4]   Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation [J].
Baldassarre, G ;
Barone, MV ;
Belletti, B ;
Sandomenico, C ;
Bruni, P ;
Spiezia, S ;
Boccia, A ;
Vento, MT ;
Romano, A ;
Pepe, S ;
Fusco, A ;
Viglietto, G .
ONCOGENE, 1999, 18 (46) :6241-6251
[5]   β-catenin mutation in rat colon tumors initiated by 1,2-dimethylhydrazine and 2-amino-3-methylimidazo[4,5-f]quinoline, and the effect of post-initiation treatment with chlorophyllin and indole-3-carbinol [J].
Blum, CA ;
Xu, MR ;
Orner, GA ;
Fong, AT ;
Bailey, GS ;
Stoner, GD ;
Horio, DT ;
Dashwood, RH .
CARCINOGENESIS, 2001, 22 (02) :315-320
[6]   A CONFIDENCE-INTERVAL FOR THE MEDIAN SURVIVAL-TIME [J].
BROOKMEYER, R ;
CROWLEY, J .
BIOMETRICS, 1982, 38 (01) :29-41
[7]   SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 [J].
Carrano, AC ;
Eytan, E ;
Hershko, A ;
Pagano, M .
NATURE CELL BIOLOGY, 1999, 1 (04) :193-199
[8]   Oligodendrocyte precursor differentiation is perturbed in the absence of the cyclin-dependent kinase inhibitor p27(Kip1) [J].
CasacciaBonnefil, P ;
Tikoo, R ;
Kiyokawa, H ;
Friedrich, V ;
Chao, MV ;
Koff, A .
GENES & DEVELOPMENT, 1997, 11 (18) :2335-2346
[9]   Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].
Catzavelos, C ;
Bhatacharya, N ;
Ung, YC ;
Wilson, JA ;
Roncari, L ;
Sandhu, C ;
Shaw, P ;
Yeger, H ;
MoravaProtzner, I ;
Kapusta, L ;
Franssen, E ;
Pritchard, KI ;
Slingerland, JM .
NATURE MEDICINE, 1997, 3 (02) :227-230
[10]   Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma [J].
Chiarle, R ;
Budel, LM ;
Skolnik, J ;
Frizzera, G ;
Chilosi, M ;
Corato, A ;
Pizzolo, G ;
Magidson, J ;
Montagnoli, A ;
Pagano, M ;
Maes, B ;
De Wolf-Peeters, C ;
Inghirami, G .
BLOOD, 2000, 95 (02) :619-626